<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002433</url>
  </required_header>
  <id_info>
    <org_study_id>062A</org_study_id>
    <secondary_id>IFNG-8901</secondary_id>
    <nct_id>NCT00002433</nct_id>
  </id_info>
  <brief_title>The Effects of r-metHuIFN-Gamma on the Lungs of Patients With AIDS</brief_title>
  <official_title>Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine safety and tolerance of administering aerosolized recombinant interferon gamma&#xD;
      (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages&#xD;
      by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of&#xD;
      IFN-gamma can activate alveolar macrophages in AIDS patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>12</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon gamma-1b</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  Diagnosis of AIDS with one or more opportunistic infections.&#xD;
&#xD;
          -  Kaposi's sarcoma with prior history of opportunistic infection.&#xD;
&#xD;
          -  Stable dose of zidovudine (AZT) therapy.&#xD;
&#xD;
          -  Preserved pulmonary, renal and hepatic function.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following conditions or symptoms are excluded:&#xD;
&#xD;
          -  Presence of active infection.&#xD;
&#xD;
          -  Active opportunistic infections.&#xD;
&#xD;
          -  Cardiac disease.&#xD;
&#xD;
          -  Central nervous system disorders.&#xD;
&#xD;
          -  History of seizures.&#xD;
&#xD;
          -  Irreversible airway disease.&#xD;
&#xD;
        Patients with the following are excluded:&#xD;
&#xD;
          -  Co-existing conditions and symptoms listed in Patient Exclusion Co-existing&#xD;
             Conditions.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 4 weeks of study entry:&#xD;
&#xD;
          -  Immunosuppressive therapy.&#xD;
&#xD;
          -  Cytotoxic therapy.&#xD;
&#xD;
          -  Excluded:&#xD;
&#xD;
          -  Interferon gamma therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New York Hosp - Cornell Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1999</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Pulmonary Alveoli</keyword>
  <keyword>Macrophage Activation</keyword>
  <keyword>Interferon-gamma, Recombinant</keyword>
  <keyword>Injections, Subcutaneous</keyword>
  <keyword>Aerosols</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-gamma</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

